Treatment of progressive multifocal leukoencephalopathy–immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab

Abstract We report a case of progressive multifocal leukoencephalopathy–immune reconstitution inflammatory syndrome in a multiple sclerosis (MS) patient 3.5 months after fingolimod commencement and 4.5 months after natalizumab (NTZ) cessation. Three cerebrospinal fluid analyses were required before...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical neuroscience 2015-03, Vol.22 (3), p.598-600
Hauptverfasser:	Calic, Z, Cappelen-Smith, C, Hodgkinson, S.J, McDougall, A, Cuganesan, R, Brew, B.J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Female Fingolimod Fingolimod Hydrochloride - therapeutic use Humans Immune Reconstitution Inflammatory Syndrome - complications Immune Reconstitution Inflammatory Syndrome - drug therapy Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Intravenous immunoglobulin Leukoencephalopathy, Progressive Multifocal - complications Leukoencephalopathy, Progressive Multifocal - drug therapy Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Natalizumab Natalizumab - therapeutic use Neurology PML–IRIS Retreatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!